Цизутамиг

Prop. INN (наименование, предложенное ВОЗ)

2919209-65-5

Immunoglobulin [[ L-kappa-H-gamma1_[VH-G1(CH1-h)]_L-kappa] dimer, anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], humanized monoclonal antibody, bispecific;
[fused L-kappa-H-gamma1 heavy chain anti-TNFRSF17 and anti-CD3E humanized (1-663) [[L-kappa anti-TNFRSF17 humanized (1-214) [V-KAPPA (Homo sapiens IGKV1-39*01 (82.1%) -IGKJ2*02 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153), V101 (191)) (108-214)] -H-gamma1 heavy chain anti-CD3E humanized (215-663) [VH (Homo sapiens IGHV1-2*02 (82.7%) -(IGHD) -IGHJ4*01 (93.3%) L123>T (328), CDR-IMGT [8.8.12] (240-247.265-272.311-322)) (215-333) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120, CH3 E12, M14, IGHG1v14 CH2 A1.3, A1.2 (CH1 R120>K (430) (334-431), hinge 1-15 (432-446), CH2 L1.3>A (450), L1.2>A (451) (447-556), CH3 E12 (572), M14 (574) (557-661), CHS (662-663)) (334-663)]]; (214-224')-disulfide with VH-G1(CH1-h) light chain anti-TNFRSF17 humanized (1'-224') [VH (Homo sapiens IGHV1-3*03 (84.7%) -IGHD -IGHJ4*01 (92.3%) L123>T (116'), CDR-IMGT [8.8.14] (26'-33'.51'-58'.97'-110')) (1'-121') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120 (CH1 R120>K (218') (122'-219'), hinge 1-5 (220'-224')) (122'-224')]]; (436-219''')-disulfide with L-kappa light chain anti-CD3E humanized (1'''-219''') [V-KAPPA (Homo sapiens IGKV4-1*01 (91.8%) -IGKJ4*01 (100%), CDR-IMGT [12.3.8] (27'''-38'''.56'''-58'''.95'''-102''')) (1'''-112''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'''), V101 (196''')) (113'''-219''')]; dimer (442-442'':445-445'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Поделиться этой страницей